Direct-acting antivirals (DAAs) have dramatically changed the landscape of hepatitis C
treatment and prevention. The World Health Organization has called for the elimination of …

Currently, access to treatment for HCV is limited, with treatment rates lowest in the more
resource-limited countries, including those countries with the highest prevalence. The use of …

Background & aims Availability of directly-acting antivirals (DAAs) has changed the
treatment landscape of hepatitis C virus (HCV) infection. The high price of DAAs has …

The introduction of direct-acting antiviral drugs (DAAs) is changing the treatment options for
hepatitis C virus (HCV). These new medicines were initially marketed at a very high price …

Objectives Seven years after the introduction of direct-acting antivirals (DAAs) for the
treatment of hepatitis C, high prices remain a barrier for treatment programs worldwide. This …

Hepatitis C affects> 3 million people in the United States, and often leads to end-stage liver
disease or death. In 2014, several new drugs to treat hepatitic C virus received US Food and …

Abstract Background Direct-acting antivirals (DAAs) for hepatitis C treatment in China
became available since 2017. This study expects to generate evidence to inform decision …

An estimated 80–150 million people are infected with hepatitis C virus (HCV) worldwide,
with the highest prevalence in low-income and medium-income countries of Africa and Asia …

Background. Several combinations of 2 or 3 direct-acting antivirals (DAAs) can cure hepatitis
C virus (HCV) in the majority of treatment-naive patients. DAAs for HCV infection have …

Hepatitis C is a global epidemic. Worldwide, 185 million people are estimated to be infected,
most of whom live in low-and middle-income countries. Recent advances in the …